ABBN.SW: $86.50 ▲ 0.40 (0.46%)ASML.AS: $1,579.80 ▲ 19.00 (1.22%)ENR.DE: $160.76 ▼ -1.74 (-1.07%)GLEN.L: $531.80 ▼ -3.50 (-0.65%)IFX.DE: $81.47 ▲ 0.91 (1.13%)NOKIA.HE: $12.38 ▲ 0.38 (3.17%)RIO.L: $7,259.00 ▼ -5.00 (-0.07%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Nuvectis Pharma, Inc.

NVCT - NASDAQ

Identifiants & Marche

Ticker NVCT
ISIN US67080T1088
CIK 0001875558
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.